Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

Recent Business Highlights: - On October 6, 2009, subsequent to the end of the third quarter, the Company received an additional Fast Track Designation from the FDA for progressive metastatic prostate cancer in combination with first- line docetaxel treatment. OncoGenex has now obtained Fast Track Designation and agreement with the FDA on trial design, via the special protocol assessment process (SPA), for two Phase 3 clinical trials in prostate cancer: one evaluating survival as the primary endpoint for patients receiving first-line docetaxel treatment, and a second evaluating pain palliation in patients receiving second-line docetaxel treatment. - The Company announced the commencement of an open label, dose- escalation, Phase 1 clinical trial evaluating OGX-427, its second product candidate, when administered directly into the bladder in patients with bladder cancer. This trial is separate from an ongoing Phase 1 trial of OGX-427 administered systemically in patients with various solid tumors. OGX-427 is a second-generation antisense drug that is designed to reduce production of Heat Shock Protein 27 (Hsp27), a cell-survival protein that inhibits apoptotic cell death through multiple pathways. - The Company completed a registered direct offering of 475,000 shares of common stock to institutional investors for gross proceeds to the Company of $9.5 million. The $20 offering price represented a 3.5% discount to the closing price on July 17, 2009, the last trading day prior to announcement.

Conference Call Today at 4:30 p.m. ET

OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today to provide a business update and discuss the third quarter results. A live webcast will be available through the Events and Presentations Web page
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... LONDON , July 31, 2014  Smith ... the global medical technology business, today announced its ... of the HAT-TRICK™ Lesser Toe Repair System. Comprised ... includes products for metatarsophalangeal (MTP) ligament repair and ... all-PEEK implant for proximal Inter-phalanges (PIP) fusion, also ...
(Date:7/31/2014)... The global market for molecular diagnostics is expected to ... new study by Grand View Research, Inc. Growing demand ... of advanced cancer diagnostic technologies are expected to be ... years. Moreover, the growing global base of geriatric population ... triggering lifestyle habits such as smoking and excessive alcohol ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... announced that it has been awarded a $1.9 million ... the National Institute of Allergy and Infectious Diseases (NIAID) ... grant will be used to perform additional preclinical toxicology ... hormone product, which is being developed as a potential ...
... SAN MARINO, Calif., Dec. 16 Epeius ... systems, has received,two additional European patents for ... enable precision gene delivery to primary cancers ... body. With profound,demonstrations of clinical benefit and ...
... -- Epitomics, Inc., the world,s sole provider of ... the appointment of Zhiqiang An, Ph.D. as Chief Scientific ... Laboratories, where he was Director of Biologics Research. He ... and development in the biotech and pharmaceutical industries, focusing ...
Cached Biology Technology:Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product 2Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate 2Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer 2Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer 3
(Date:7/31/2014)... According to the U.S. Census Bureau, Latinos are the ... of the population. Approximately one-third of Latinos are ... obese compared to non-Hispanic Whites. , NYU College ... candidate, has sought to identify the factors that contribute ... qualitative studies that focused on food patterns in Latina ...
(Date:7/31/2014)... Researchers who studied 100 twin pairs have identified a gene ... less than six hours of sleep per night. The ... effects of sleep deprivation. , Results show that a participant ... had an average nightly sleep duration of only five hours, ... twin, who slept for about six hours and five minutes ...
(Date:7/31/2014)... hazard lurks beneath many of the roughly 156,000 ... hazard is corrosion in parts of underground gas ... and contamination of groundwater, a source of drinking ... states have reported many rapidly corroding gas storage ... are generally associated with use of gasoline-ethanol blends ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Study of twins discovers gene mutation linked to short sleep duration 2NIST corrosion lab tests suggest need for underground gas tank retrofits 2
... . The scientists observed that the impact of ... study have been published in the current online issue of the ... to show that children who are exposed to tobacco smoke prenatally ... of developing abnormal behavioral symptoms when they are of school age," ...
... , WALL, N.J., Dec. 9 ... a leader in finger-based biometric identification solutions, today ... most respected security publications, named BIO-key International the ... Control sub-category Biometrics. , (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ...
... in old age or diabetes, leads to low blood flow ... tissues. Such blockages can require amputation resulting in loss of ... Hopkins have developed therapies that increase blood flow, improve movement ... findings, published online last week in the early edition of ...
Cached Biology News:Study confirms association between tobacco smoke and behavioral problems in children 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Gene therapy and stem cells save limb 2Gene therapy and stem cells save limb 3
... Rotor designed for use in the ... Centra-MP4/MP4R*. A translucent lid is included ... rotor design provides excellent chemical resistance ... Polypropylene rotors are fully compatible with ...
Medium bottle for hybridization 250 x 35mm...
Extra Large bottle for hybridization 300 x 70mm...
CQCS kit for first KR 4i , (first unit)....
Biology Products: